Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs.
LEARN MORETriple-action, once-a-day treatment for 7 days for even the most stubborn cases associated with susceptible strains of yeast and bacteria in canines.
LEARN MOREFor induction of estrus in prepuberal gilts and healthy weaned sows experiencing delayed return to estrus.
LEARN MORE